Nanobiotix S.A. Form 6-K Summary
Business Context and Reporting Period
Nanobiotix S.A. filed this Form 6-K on November 7, 2023. The filing reports a global equity offering and a concurrent private placement with Johnson & Johnson Innovation–JJDC, Inc. It does not provide quarterly or annual operating results.
Financing and Key Financial Metrics
- U.S. offering: 3,106,907 ADSs at $5.36 per ADS, before the over-allotment exercise.
- U.S. over-allotment: Underwriters exercised an option for an additional 680,000 ADSs at $5.36 per ADS. The total U.S. offering therefore comprised 3,786,907 ADSs, representing approximately $20.3 million in gross proceeds before fees and expenses.
- European offering: 2,492,223 ordinary shares at €5.07 per share, representing approximately €12.6 million in gross proceeds before fees and expenses.
- JJDC private placement: JJDC initially subscribed for 3,762,923 restricted ADSs for $20.2 million. Subject to approval by the French Ministry of Economy, JJDC may subscribe for an additional 901,256 restricted ADSs for $4.8 million, completing the previously agreed $25.0 million placement amount.
- Liquidity and debt: The filing does not provide cash balances, cash burn, debt, revenue, profit, margins, or cash-flow figures.
Material Changes and Transaction Status
The transaction expands the previously announced JJDC investment while initially limiting JJDC’s ownership to 9.99% of outstanding voting rights under French foreign investment control rules. The public offering and U.S. option exercise were expected to close on November 7, 2023, subject to customary conditions. The initial JJDC placement was expected to close on November 9, 2023, subject to completion of the public offerings.
The securities were offered under the Company’s effective Form F-3 registration statement and related prospectus supplement. The JJDC securities were issued pursuant to the private-placement exemption under Section 4(a)(2) of the Securities Act.
Outlook, Risks, and Unusual Items
- The additional $4.8 million JJDC subscription depends on approval from the French Ministry of Economy.
- All stated closing dates were expected dates and remained subject to applicable closing conditions.
- The offerings will increase the number of outstanding shares and ADSs, creating potential dilution for existing shareholders.
- The Underwriting Agreement contains customary representations, warranties, covenants, indemnification obligations, and underwriter liability provisions.
- The filing provides no business guidance, clinical-development outlook, revenue forecast, or management discussion of operating risks.
Facts Investors Should Verify
- Whether the global offering closed as expected and the final gross and net proceeds after underwriting discounts and expenses.
- Whether the initial and additional JJDC subscriptions closed, including the required French regulatory approval.
- The final number of shares and ADSs outstanding and the resulting ownership and dilution percentages.
- The Company’s cash runway, operating cash burn, debt obligations, and use of proceeds, which are not disclosed in this filing.
- Any subsequent filings reporting completion of the transactions or amendments to the financing terms.